Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions

References

• MitchellJDBorasioGDAmyotrophic lateral sclerosisLancet200736995782031204117574095
   PubMed Web of Science ®Google Scholar
• StrongMJAbrahamsSGoldsteinLHAmyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteriaAmyotroph Lateral Scler Frontotemporal Degener2017183–415317428054827
   PubMed Web of Science ®Google Scholar
• TraynorBJAlexanderMCorrBFrostEHardimanOEffect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000J Neurol Neurosurg Psychiatry20037491258126112933930
   PubMed Web of Science ®Google Scholar
• JawaidAMurthySBWilsonAMA decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALSAmyotrophic Lateral Sclerosis201011654254820500116
   PubMed Web of Science ®Google Scholar
• MarinBDesportJCKajeuPAlteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patientsJ Neurol Neurosurg Psychiatry201182662863421097551
   PubMed Web of Science ®Google Scholar
• GentonLViatteVJanssensJPHeritierACPichardCNutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patientsClin Nutr201130555355921798636
   PubMed Web of Science ®Google Scholar
• PaganoniSDengJJaffaMCudkowiczMEWillsAMBody mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosisMuscle Nerve2011441202421607987
   PubMed Web of Science ®Google Scholar
• MillerRGJacksonCEKasarskisEJPractice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence-based review)Neurology2009731227123319822873
   PubMed Web of Science ®Google Scholar
• AhmedRMCagaJDevenneyECognition and eating behavior in amyotrophic lateral sclerosis: effect on survivalJ Neurol201626381593160327260291
   PubMed Web of Science ®Google Scholar
• CastonguayTWApplegateEAUptonDESternJSHunger and appetite: old concepts/new distinctionsNutr Rev19834141011106346147
   PubMed Web of Science ®Google Scholar
• HolmTMaierAWicksPSevere loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment studyInteract J Med Res201321e823608722
   PubMedGoogle Scholar
• RobbinsJSwallowing in ALS and motor neuron disordersNeurol Clin19875221322911681400
   PubMed Web of Science ®Google Scholar
• NeudertCOliverDWasnerMBorasioGDThe course of the terminal phase in patients with amyotrophic lateral sclerosisJ Neurol200124861261611518004
   PubMed Web of Science ®Google Scholar
• MuscaritoliMKushtaIMolfinoAInghilleriMSabatelliMRossi FanelliFNutritional and metabolic support in patients with amyotrophic lateral sclerosisNutrition2012281095996622677356
   PubMed Web of Science ®Google Scholar
• KornerSHendricksMKolleweKWeight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic optionsBMC Neurol2013131848423848967
   PubMed Web of Science ®Google Scholar
• HeffernanCJenkinsonCHolmesTNutritional management in MND/ALS patients: an evidence based reviewAmyotroph Lateral Scler Other Motor Neuron Disord200452728315204009
   PubMed Web of Science ®Google Scholar
• SilaniVKasarskisEJYanagisawaNNutritional management in amyotrophic lateral sclerosis: a worldwide perspectiveJ Neurol1998245Suppl 2S13S19 discussion S299747929
   PubMed Web of Science ®Google Scholar
• GreenwoodDINutrition management of amyotrophic lateral sclerosisNutr Clin Pract201328339239923466470
   PubMed Web of Science ®Google Scholar
• AndersenPMBorasioGDDenglerRGood practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working GroupAmyotroph Lateral Scler20078419521317653917
   PubMed Web of Science ®Google Scholar
• ToepferCFAKRLMGastrointestinal dysfunction in amyotrophic lateral sclerosisAmyotrophic Lateral Scler Other Motor Neuron Disord2009111519
   Google Scholar
• NgoSTSteynFJHuangLAltered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosisJ Neurol Sci20153571–2222726198021
   PubMed Web of Science ®Google Scholar
• ChaudhriOSmallCBloomSGastrointestinal hormones regulating appetitePhilos Trans R Soc Lond B Biol Sci200636114711187120916815798
   PubMed Web of Science ®Google Scholar
• AndrewsZBAbizaidANeuroendocrine mechanisms that connect feeding behavior and stressFront Neurosci2014831225324716
   PubMed Web of Science ®Google Scholar
• AhmedRMIrishMPiguetOAmyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolismLancet Neurol201615333234226822748
   PubMed Web of Science ®Google Scholar
• VercruyssePSinnigerJEl OussiniHAlterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosisBrain2016139Pt 41106112226984187
   PubMed Web of Science ®Google Scholar
• CykowskiMDTakeiHSchulzPEAppelSHPowellSZTDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosisActa Neuropathol Commun2014217125539830
   PubMed Web of Science ®Google Scholar
• KasarskisEJBerrymanSVanderleestJGSchneiderARMcClainCJNutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of deathAm J Clin Nutr19966311301378604660
   PubMed Web of Science ®Google Scholar
• DesportJCPreuxPMMagyLFactors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.(Brief Article)Am J Clin Nutr200174332811522556
   PubMed Web of Science ®Google Scholar
• IoannidesZANgoSTHendersonRDMcCombePASteynFJAltered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progressionNeurodegener Dis2016165–638239727400276
   PubMed Web of Science ®Google Scholar
• BouteloupCDesportJCClavelouPHypermetabolism in ALS patients: an early and persistent phenomenonJ Neurol200925681236124219306035
   PubMed Web of Science ®Google Scholar
• FrostJOkunSVaughanTHeywoodJWicksPPatient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMeJ Med Internet Res2011131e621252034
   PubMed Web of Science ®Google Scholar
• BradleyWGAndersonFGowdaNMillerRGGroup ACSChanges in the management of ALS since the publication of the AAN ALS practice parameter 1999Amyotroph Lateral Scler Other Motor Neuron Disord20045424024415799554
   PubMed Web of Science ®Google Scholar
• SalvioniCCStanichPAlmeidaCSOliveiraASNutritional care in motor neurone disease/amyotrophic lateral sclerosisArq Neuropsiquiatr201472215716324604371
   PubMed Web of Science ®Google Scholar
• SpataroRFicanoLPiccoliFLa BellaVPercutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survivalJ Neurol Sci20113041–2444821371720
   PubMed Web of Science ®Google Scholar
• FasanoAFiniNFerraroDPercutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry studyAmyotroph Lateral Scler Frontotemporal Degener2017110
   Web of Science ®Google Scholar
• MockfordCJenkinsonCFitzpatrickRA review: carers, MND and service provisionAmyotroph Lateral Scler20067313214116963402
   PubMed Web of Science ®Google Scholar
• MNDAEating and drinking with motor neurone disease (MND)2017 Available from: https://www.mndassociation.org/wp-content/uploads/Eating-and-drinking-with-MND-final-web-PDF-2017.pdfAccessed June 16, 2017
   Google Scholar
• RioACawadiasENutritional advice and treatment by dietitians to patients with amyotrophic lateral sclerosis/motor neurone disease: a survey of current practice in England, Wales, Northern Ireland and CanadaJ Hum Nutr Diet200720131317241187
   PubMed Web of Science ®Google Scholar
• KasarskisEJMendiondoMSMatthewsDEEstimating daily energy expenditure in individuals with amyotrophic lateral sclerosisAm J Clin Nutr201499479280324522445
   PubMed Web of Science ®Google Scholar
• ProGas StudyGGastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort studyLancet Neurol201514770270926027943
   PubMed Web of Science ®Google Scholar
• Rahnemai-AzarAARahnemaiazarAANaghshizadianRKurtzAFarkasDTPercutaneous endoscopic gastrostomy: indications, technique, complications and managementWorld J Gastroenterol201420247739775124976711
   PubMed Web of Science ®Google Scholar
• StavroulakisTWalshTShawPJMcDermottCJProgasSGastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practiceAmyotroph Lateral Scler Frontotemporal Degener20131429610422985431
   PubMed Web of Science ®Google Scholar
• WillsA-MHubbardJMacklinEAHypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trialLancet201438399342065207224582471
   PubMed Web of Science ®Google Scholar
• MattsonMPCutlerRGCamandolaSEnergy intake and amyotrophic lateral sclerosisNeuromolecular Med200791172017114821
   PubMed Web of Science ®Google Scholar
• SilvaLBdCMourãoLFSilvaAAEffect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patientsArquivos de Neuro-Psiquiatria20106826326820464297
   PubMed Web of Science ®Google Scholar
• DorstJCypionkaJLudolphACHigh-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional studyAmyotroph Lateral Scler Frontotemporal Degener2013147–853353623944684
   PubMed Web of Science ®Google Scholar
• ThomasBFElSohlyMAChapter 1 – The botany of Cannabis sativa LThe Analytical Chemistry of CannabisElsevier2016126
   Google Scholar
• Di MarzoVBifulcoMDe PetrocellisLThe endocannabinoid system and its therapeutic exploitationNat Rev Drug Discov20043977178415340387
   PubMed Web of Science ®Google Scholar
• GrotenhermenFMuller-VahlKThe therapeutic potential of cannabis and cannabinoidsDtsch Arztebl Int201210929–3049550123008748
   PubMed Web of Science ®Google Scholar
• AlexanderSPTherapeutic potential of cannabis-related drugsProg Neuropsychopharmacol Biol Psychiatry20166415716626216862
   PubMed Web of Science ®Google Scholar
• AmtmannDWeydtPJohnsonKLJensenMPCarterGTSurvey of cannabis use in patients with amyotrophic lateral sclerosisAm J Hosp Palliat Care20042129510415055508
   PubMedGoogle Scholar
• CarterGTAboodMEAggarwalSKWeissMDCannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trialsAm J Hosp Palliat Care201027534735620439484
   PubMed Web of Science ®Google Scholar
• CowleyMASmartJLRubinsteinMLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleusNature2001411683648048411373681
   PubMed Web of Science ®Google Scholar
• KochMVarelaLKimJGHypothalamic POMC neurons promote cannabinoid-induced feedingNature20155197541455025707796
   PubMed Web of Science ®Google Scholar
• KalraSPHorvathTLNeuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetiteAnn N Y Acad Sci19988632362409928174
   PubMed Web of Science ®Google Scholar
• ManfrediGXuZMitochondrial dysfunction and its role in motor neuron degeneration in ALSMitochondrion200552778716050975
   PubMed Web of Science ®Google Scholar
• CozzolinoMCarriMTMitochondrial dysfunction in ALSProg Neurobiol2012972546621827820
   PubMed Web of Science ®Google Scholar
• MuydermanHChenTMitochondrial dysfunction in amyotrophic lateral sclerosis – a valid pharmacological target?Br J Pharmacol201417182191220524148000
   PubMed Web of Science ®Google Scholar
• VolkowNDBalerRDComptonWMWeissSRAdverse health effects of marijuana useN Engl J Med2014370232219222724897085
   PubMed Web of Science ®Google Scholar
• WrenAMSealLJCohenMAGhrelin enhances appetite and increases food intake in humansJ Clin Endocrinol Metab20018612599211739476
   PubMed Web of Science ®Google Scholar
• CzellDBaldingerRSchneiderUNeuwirthCWeberMThe role of the SenseWear device and ghrelin for metabolism in amyotrophic lateral sclerosisAmyotroph Lateral Scler Frontotemporal Degener2016173–4295296
   PubMed Web of Science ®Google Scholar
• LimELeeSLiEKimYParkSGhrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3beta pathwaysExp Neurol2011230111412221530509
   PubMed Web of Science ®Google Scholar
• LeeSKimYLiEParkSGhrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activationKorean J Physiol Pharmacol2012161434822416219
   PubMed Web of Science ®Google Scholar
• ColldénGTschopMHMullerTDTherapeutic potential of targeting the ghrelin pathwayInt J Mol Sci2017184E79828398233
   PubMed Web of Science ®Google Scholar
• XuHHuangXRiserusUDietary fiber, kidney function, inflammation, and mortality riskClin J Am Soc Nephrol20149122104211025280496
   PubMed Web of Science ®Google Scholar
• YoungRPHopkinsRJHigh dietary fiber lowers systemic inflammation: potential utility in COPD and lung cancerAm J Med20141278e13
   Web of Science ®Google Scholar
• SlavinJFiber and prebiotics: mechanisms and health benefitsNutrients2013541417143523609775
   PubMed Web of Science ®Google Scholar
• FondellEO’ReillyEJFitzgeraldKCDietary fiber and amyotrophic lateral sclerosis: results from 5 large cohort studiesAm J Epidemiol2014179121442144924816788
   PubMed Web of Science ®Google Scholar
• NievesJWGenningsCFactor-LitvakPAssociation between dietary intake and function in amyotrophic lateral sclerosisJAMA Neurol201673121425143227775751
   PubMed Web of Science ®Google Scholar
• HanischFSkudlarekABerndtJKornhuberMECharacteristics of pain in amyotrophic lateral sclerosisBrain Behav201553e0029625642388
   PubMed Web of Science ®Google Scholar
• LayzerRBDiagnostic implications of clinical fasciculation and crampsAdv Neurol19823623297180684
   PubMedGoogle Scholar
• GubbaySSKahanaEZilberNCooperGPintovSLeibowitzYAmyotrophic lateral sclerosis. A study of its presentation and prognosisJ Neurol198523252953004056836
   PubMed Web of Science ®Google Scholar
• LayzerRBThe origin of muscle fasciculations and crampsMuscle Nerve19941711124312497935546
   PubMed Web of Science ®Google Scholar
• BaldisseraFCavallariPDworzakFMotor neuron ‘bistability’. A pathogenetic mechanism for cramps and myokymiaBrain1994117Pt 59299397953602
   PubMed Web of Science ®Google Scholar
• ObiTMizoguchiKMatsuokaHTakatsuMNishimuraYMuscle cramp as the result of impaired GABA function–an electrophysiological and pharmacological observationMuscle Nerve19931611122812318413375
   PubMed Web of Science ®Google Scholar
• MillerRGJacksonCEKasarskisEJQuality Standards Subcommittee of the American Academy of NeurologyPractice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200973151227123319822873
   PubMed Web of Science ®Google Scholar
• AchanJTalisunaAOErhartAQuinine, an old anti-malarial drug in a modern world: role in the treatment of malariaMalar J20111014421609473
   PubMed Web of Science ®Google Scholar
• Man-Son-HingMWellsGLauAQuinine for nocturnal leg cramps: a meta-analysis including unpublished dataJ Gen Intern Med19981396006069754515
   PubMed Web of Science ®Google Scholar
• DysonEHProudfootATPrescottLFHeyworthRDeath and blindness due to overdose of quinineBr Med J (Clin Res Ed)198529164873133
   Web of Science ®Google Scholar
• TuckerJMTownsendDMAlpha-tocopherol: roles in prevention and therapy of human diseaseBiomed Pharmacother200559738038716081238
   PubMed Web of Science ®Google Scholar
• AyresSJrMihanRLeg cramps (systremma) and “restless legs” syndrome. Response to vitamin E (tocopherol)Calif Med1969111287915346435
   PubMedGoogle Scholar
• Michal FreedmanDKunclRWWeinsteinSJMalilaNVirtamoJAlbanesDVitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosisAmyotroph Lateral Scler Frontotemporal Degener201314424625123286756
   PubMed Web of Science ®Google Scholar
• de BustosFJimenez-JimenezFJMolinaJACerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosisJ Neural Transm (Vienna)19981056–77037089826112
   PubMed Web of Science ®Google Scholar
• IwasakiYIkedaKKinoshitaMVitamin A and E levels are normal in amyotrophic lateral sclerosisJ Neurol Sci199513221931948543947
   PubMed Web of Science ®Google Scholar
• WangHO’ReillyEJWeisskopfMGVitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studiesAm J Epidemiol2011173659560221335424
   PubMed Web of Science ®Google Scholar
• VeldinkJHKalmijnSGroeneveldGJIntake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosisJ Neurol Neurosurg Psychiatry200778436737116648143
   PubMed Web of Science ®Google Scholar
• AscherioAWeisskopfMGO’ReillyEJVitamin E intake and risk of amyotrophic lateral sclerosisAnn Neurol200557110411015529299
   PubMed Web of Science ®Google Scholar
• KwiecinskiHJanikPJamrozikZOpuchlikAThe effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trialsNeurol Neurochir Pol2001351 Suppl101106
   PubMedGoogle Scholar
• DesnuelleCDibMGarrelCFavierAA double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study GroupAmyotroph Lateral Scler Other Motor Neuron Disord20012191811465936
   PubMed Web of Science ®Google Scholar
• GalbusseraATremolizzoLBrighinaLVitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series studyNeurol Sci200627319019316897634
   PubMed Web of Science ®Google Scholar
• GrafMEckerDHorowskiRHigh dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJ Neural Transm (Vienna)2005112564966015517433
   PubMed Web of Science ®Google Scholar
• DurlachJBacPBaraMGuiet-BaraAPhysiopathology of symptomatic and latent forms of central nervous hyperexcitability due to magnesium deficiency: a current general schemeMagnes Res200013429330211153899
   PubMed Web of Science ®Google Scholar
• SeboPCeruttiBHallerDMEffect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulationsFam Pract201431171924280947
   PubMed Web of Science ®Google Scholar
• FondellEO’ReillyEJFitzgeraldKCMagnesium intake and risk of amyotrophic lateral sclerosis: results from five large cohort studiesAmyotroph Lateral Scler Frontotemporal Degener2013145–635636123777266
   PubMed Web of Science ®Google Scholar
• LongneckerMPKamelFUmbachDMDietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosisNeuroepidemiology200019421021610859501
   PubMed Web of Science ®Google Scholar
• ChangEGhoshNYanniDLeeSAlexandruDMozaffarTA review of spasticity treatments: pharmacological and interventional approachesCrit Rev Phys Rehabil Med2013251–2112225750484
   PubMedGoogle Scholar
• KhederANairKPSpasticity: pathophysiology, evaluation and managementPract Neurol201212528929822976059
   PubMedGoogle Scholar
• SimonOYelnikAPManaging spasticity with drugsEur J Phys Rehabil Med201046340141020927006
   PubMed Web of Science ®Google Scholar
• MaherTJWurtmanRJl-threonine administration increases glycine concentrations in the rat central nervous systemLife Sci19802616128312866770208
   PubMedGoogle Scholar
• TestaDCaraceniTFetoniVGirottiFChronic treatment with l-threonine in amyotrophic lateral sclerosis: a pilot studyClin Neurol Neurosurg1992941791353011
   PubMed Web of Science ®Google Scholar
• LeeAPattersonVA double-blind study of l-threonine in patients with spinal spasticityActa Neurol Scand19938853343388296531
   PubMed Web of Science ®Google Scholar
• BlinOPougetJAubrespyGGueltonCCrevatASerratriceGA double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosisJ Neurol1992239279811313078
   PubMed Web of Science ®Google Scholar
• NgLKhanFYoungCAGaleaMSymptomatic treatments for amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database Syst Rev20171CD01177628072907
   PubMed Web of Science ®Google Scholar
• PetroDJEllenbergerCJrTreatment of human spasticity with delta 9-tetrahydrocannabinolJ Clin Pharmacol1981218–9 Suppl413S416S6271839
   PubMed Web of Science ®Google Scholar
• PryceGBakerDEndocannabinoids in multiple sclerosis and amyotrophic lateral sclerosisHandb Exp Pharmacol201523121323126408162
   PubMedGoogle Scholar
• FlacheneckerPHenzeTZettlUKNabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityEur Neurol2014715–627127924525548
   PubMed Web of Science ®Google Scholar
• FernandezOAdvances in the management of MS spasticity: recent observational studiesEur Neurol201472Suppl 1121425278118
   PubMed Web of Science ®Google Scholar
• BilslandLGDickJRPryceGIncreasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 miceFASEB J20062071003100516571781
   PubMed Web of Science ®Google Scholar
• ShoemakerJLSeelyKAReedRLCrowJPPratherPLThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJ Neurochem20071011879817241118
   PubMed Web of Science ®Google Scholar
• RossiSDe ChiaraVMusellaAAbnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosisAmyotroph Lateral Scler2010111–2839019452308
   PubMed Web of Science ®Google Scholar
• WeberMGoldmanBTrunigerSTetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trialJ Neurol Neurosurg Psychiatry201081101135114020498181
   PubMed Web of Science ®Google Scholar
• Group ALALSUntangled No. 16: cannabisAmyotroph Lateral Scler201213440040422632446
   PubMed Web of Science ®Google Scholar
• NehligADavalJLDebryGCaffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effectsBrain Res Brain Res Rev19921721391701356551
   PubMed Web of Science ®Google Scholar
• PotenzaRLArmidaMFerranteAEffects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosisJ Neurosci Res201391458559223361938
   PubMed Web of Science ®Google Scholar
• FondellEO’ReillyEIFitzgeraldKCIntakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: results from five cohort studiesAmyotroph Lateral Scler Frontotemporal Degener2015165–636637125822002
   PubMed Web of Science ®Google Scholar
• BeghiEPupilloEMessinaPCoffee and amyotrophic lateral sclerosis: a possible preventive roleAm J Epidemiol201117491002100821946385
   PubMed Web of Science ®Google Scholar
• Onatibia-AstibiaAFrancoRMartinez-PinillaEHealth benefits of methylxanthines in neurodegenerative diseasesMol Nutr Food Res2017
   Web of Science ®Google Scholar
• YenisettiSCManjunathMJMuralidharaCNeuropharmacological properties of Withania somnifera – Indian Ginseng: an overview on experimental evidence with emphasis on clinical trials and patentsRecent Pat CNS Drug Discov201610220421527316579
   PubMedGoogle Scholar
• KolahdouzanMHamadehMJThe neuroprotective effects of caffeine in neurodegenerative diseasesCNS Neurosci Ther201723427229028317317
   PubMed Web of Science ®Google Scholar
• ADBThe ketogenic diet in epilepsyCan Med Assoc J193124110610720318124
   PubMedGoogle Scholar
• PetermanMGThe ketogenic diet in epilepsyJAMA1925842619791983
   Google Scholar
• StafstromCERhoJMThe ketogenic diet as a treatment paradigm for diverse neurological disordersFront Pharmacol201235922509165
   PubMed Web of Science ®Google Scholar
• GasiorMRogawskiMAHartmanALNeuroprotective and disease-modifying effects of the ketogenic dietBehav Pharmacol2006175–643143916940764
   PubMed Web of Science ®Google Scholar
• PaoliABiancoADamianiEBoscoGKetogenic diet in neuromuscular and neurodegenerative diseasesBiomed Res Int2014201447429625101284
   PubMed Web of Science ®Google Scholar
• VidaliSAminzadehSLambertBMitochondria: The ketogenic diet–A metabolism-based therapyInt J Biochem Cell Biol201563555925666556
   PubMed Web of Science ®Google Scholar
• Echaniz-LagunaAZollJRiberaFMitochondrial respiratory chain function in skeletal muscle of ALS patientsAnn Neurol200252562362712402260
   PubMed Web of Science ®Google Scholar
• WiedemannFRWinklerKKuznetsovAVImpairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosisJ Neurol Sci1998156165729559989
   PubMed Web of Science ®Google Scholar
• VielhaberSWinklerKKirchesEVisualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosisJ Neurol Sci19991691–213313910540022
   PubMed Web of Science ®Google Scholar
• SicilianoGPastoriniEPasqualiLMancaMLIudiceAMurriLImpaired oxidative metabolism in exercising muscle from ALS patientsJ Neurol Sci20011911–2616511676993
   PubMed Web of Science ®Google Scholar
• CrugnolaVLampertiCLucchiniVMitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosisArch Neurol201067784985420625092
   PubMed Web of Science ®Google Scholar
• PalamiucLSchlagowskiANgoSTA metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosisEMBO Mol Med20157552654625820275
   PubMed Web of Science ®Google Scholar
• PradatPFBruneteauGGordonPHImpaired glucose tolerance in patients with amyotrophic lateral sclerosisAmyotroph Lateral Scler2010111–216617120184518
   PubMed Web of Science ®Google Scholar
• ZhaoZLangeDJVoustianioukAA ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosisBMC Neurosci200672916584562
   PubMed Web of Science ®Google Scholar
• PaoliARubiniAVolekJSGrimaldiKABeyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) dietsEur J Clin Nutr201367878979623801097
   PubMed Web of Science ®Google Scholar
• ALS Untangled GroupFournierCBedlackBALS Untangled No. 20: the Deanna protocolAmyotroph Lateral Scler Frontotemporal Degener201314431932323638638
   PubMed Web of Science ®Google Scholar
• MoncadaSHiggsAThe L-arginine-nitric oxide pathwayN Engl J Med199332927200220127504210
   PubMed Web of Science ®Google Scholar
• AriCPoffAMHeldHEMetabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse modelPLoS One201497e10352625061944
   PubMed Web of Science ®Google Scholar
• WalkerJBCreatine: biosynthesis, regulation, and functionAdv Enzymol Relat Areas Mol Biol197950177242386719
   PubMedGoogle Scholar
• CaseyAGreenhaffPLDoes dietary creatine supplementation play a role in skeletal muscle metabolism and performance?Am J Clin Nutr2000722 Suppl607S617S10919967
   PubMed Web of Science ®Google Scholar
• O’GormanEBeutnerGWallimannTBrdiczkaDDifferential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brainBiochim Biophys Acta1996127621611708816948
   PubMed Web of Science ®Google Scholar
• StrongMJPatteeGLCreatine and coenzyme Q10 in the treatment of ALSAmyotroph Lateral Scler Other Motor Neuron Disord20001Suppl 4172011466954
   PubMed Web of Science ®Google Scholar
• KlivenyiPFerranteRJMatthewsRTNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosisNat Med19995334735010086395
   PubMed Web of Science ®Google Scholar
• AndreassenOAJenkinsBGDedeogluAIncreases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementationJ Neurochem200177238339011299300
   PubMed Web of Science ®Google Scholar
• DeraveWVan Den BoschLLemmensGEijndeBORobberechtWHespelPSkeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatmentNeurobiol Dis200313326427212901841
   PubMed Web of Science ®Google Scholar
• MazziniLBalzariniCColomboREffects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary resultsJ Neurol Sci20011911–213914411677005
   PubMed Web of Science ®Google Scholar
• RosenfeldJKingRMJacksonCECreatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRSAmyotrophic Lateral Sclerosis20089526627218608103
   PubMed Web of Science ®Google Scholar
• DroryVEGrossDNo effect of creatine on respiratory distress in amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord200231434612061948
   PubMed Web of Science ®Google Scholar
• PastulaDMMooreDHBedlackRSCreatine for amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database Syst Rev201212CD00522523235621
   PubMed Web of Science ®Google Scholar
• KulieTGroffARedmerJHounshellJSchragerSVitamin D: an evidence-based reviewJ Am Board Fam Med200922669870619897699
   PubMed Web of Science ®Google Scholar
• GianforcaroASolomonJAHamadehMJVitamin D(3) at 50× AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in femalesPLoS One201382e3024323405058
   PubMed Web of Science ®Google Scholar
• GianforcaroAHamadehMJDietary vitamin D3 supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot studyCNS Neurosci Ther201218754755722591278
   PubMed Web of Science ®Google Scholar
• CamuWTremblierBPlassotCVitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosisNeurobiol Aging20143551198120524378089
   PubMed Web of Science ®Google Scholar
• KaramCBarrettMJImperatoTMacGowanDJScelsaSVitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosisJ Clin Neurosci201320111550155323815870
   PubMed Web of Science ®Google Scholar
• McCordJMThe evolution of free radicals and oxidative stressAm J Med2000108865265910856414
   PubMed Web of Science ®Google Scholar
• D’AmicoEFactor-LitvakPSantellaRMMitsumotoHClinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosisFree Radic Biol Med20136550952723797033
   PubMed Web of Science ®Google Scholar
• OrrellRWLaneRJRossMA systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron diseaseAmyotroph Lateral Scler20089419521118608090
   PubMed Web of Science ®Google Scholar
• OrrellRWLaneRJRossMAntioxidant treatment for amyotrophic lateral sclerosis / motor neuron diseaseCochrane Database Syst Rev20071CD00282917253482
   PubMed Web of Science ®Google Scholar
• ReynoldsEVitamin B12, folic acid, and the nervous systemLancet Neurol200651194996017052662
   PubMed Web of Science ®Google Scholar
• WatanabeFVitamin B12 sources and bioavailabilityExp Biol Med (Maywood)2007232101266127417959839
   PubMed Web of Science ®Google Scholar
• KajiRKodamaMImamuraAEffect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled studyMuscle Nerve19982112177517789843082
   PubMed Web of Science ®Google Scholar
• KajiRKuzuharaSIwasakiYUltra-high dose methylcobalamin (E0302) prolongs survival of ALS: report of 7 years’ randomised double-blind, phase 3 clinical trial (ClinicalTrials.gov NCT00444613)Paper presented at: AAN Annual Meeting2015
   Google Scholar
• ALS-UntangledALSUntangled No. 30: methylcobalaminAmyotroph Lateral Scler Frontotemporal Degener2015167–853653926203660
   PubMed Web of Science ®Google Scholar
• GulcinIAntioxidant and antiradical activities of L-carnitineLife Sci200678880381116253281
   PubMed Web of Science ®Google Scholar
• BeghiEPupilloEBonitoVRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALSAmyotroph Lateral Scler Frontotemporal Degener2013145–639740523421600
   PubMed Web of Science ®Google Scholar
• TurunenMOlssonJDallnerGMetabolism and function of coenzyme QBiochim Biophys Acta200416601–217119914757233
   PubMed Web of Science ®Google Scholar
• FerranteKLShefnerJZhangHTolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSNeurology200565111834183616344537
   PubMed Web of Science ®Google Scholar
• KaufmannPThompsonJLLevyGPhase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIAnn Neurol200966223524419743457
   PubMed Web of Science ®Google Scholar
• KelsoGFPorteousCMCoulterCVSelective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic propertiesJ Biol Chem200127674588459611092892
   PubMed Web of Science ®Google Scholar
• MiquelECassinaAMartinez-PalmaLNeuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosisFree Radic Biol Med20147020421324582549
   PubMed Web of Science ®Google Scholar
• SnowBJRolfeFLLockhartMMProtect Study GroupA double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s diseaseMov Disord201025111670167420568096
   PubMed Web of Science ®Google Scholar
• WatanabeTTaharaMTodoSThe novel antioxidant edaravone: from bench to bedsideCardiovasc Ther200826210111418485133
   PubMed Web of Science ®Google Scholar
• AokiMWaritaHMizunoHSuzukiNYukiSItoyamaYFeasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavengerBrain Res2011138232132521276427
   PubMed Web of Science ®Google Scholar
• ItoHWateRZhangJTreatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS miceExp Neurol2008213244845518718468
   PubMed Web of Science ®Google Scholar
• AbeKItoyamaYSobueGConfirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patientsAmyotroph Lateral Scler Frontotemporal Degener2014157–861061725286015
   PubMed Web of Science ®Google Scholar
• TanakaMSakataTPalumboJAkimotoMA 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS)Paper presented at: AAN Annual Meeting2016Vancouver, Canada
   Google Scholar
• PetrovDMansfieldCMoussyAHermineOALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment?Front Aging Neurosci201796828382000
   PubMed Web of Science ®Google Scholar